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Abstract
Background: Greater access and prolonged exposure to ART may inevitably lead to more treatment failure and increase the 
need for third-line ART (TLART) in a resource-limited setting. 
Objective: To describe characteristics and resistance patterns of  adult patients initiated on TLART in three districts of  the 
North West province.
Method: All-inclusive retrospective descriptive investigation. Demographics and clinical variables were recorded from adult 
patient health records (2002-2017) and analysed.
Results: 21 Patients (17 females, 4 males) with median (IQR) age of  34 years (30.2-37.8) at HIV diagnosis and 45 years 
(39.5-47) at TLART initiation were included. Median duration (days) from HIV diagnosis to first-line ART initiation was 
101 (37-367), treatment duration on first-line, second-line and between second-line failure and TLART initiation were: 1 269 
(765-2 343); 1 512 (706-2096) and 71 (58-126) days respectively.
High-level resistance most prevalent were: nelfinavir/r (85.7%), indinavir/r (80.9%), lopinavir/r (76.2%), emtricitabine and 
lamivudine (95.2%), nevirapine (76.2%) and efavirenz (71.4%).  Resistance to 3 major PI mutations in 95% of  patients and 
cross resistance were documented extensively.
Conclusion: This study support the need for earlier resistance testing.  It firstly reported on time duration post diagnosis on 
various ART regimens and secondly resistance patterns of  adults before TLART was initiated in these districts.
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Introduction
Human immunodeficiency virus (HIV) infection re-
mains a global pandemic, with an estimated 36.7 million 
people living with HIV globally at the end of  20161,2. 
UNAIDS set out the ambitious 90-90-90 targets to be 
reached by end of  2020, where 90% of  people living 
with HIV should be diagnosed, 90% of  the people di-
agnosed with HIV should receive antiretroviral ther-
apy (ART) and 90% of  those receiving ART should 
be virally suppressed to accomplish the eradication of  
the acquired immune deficiency syndrome (AIDS) by 
20303.
The number of  people globally having access to ART 
was reported as 20.9 million in June 20172. South Afri-
ca, however, has the biggest epidemic in the world with 
an estimated 7.06 million HIV positive people in June 
2017, which represents 12.6% of  the total population 
and 18.0% of  its adult population aged between 15 and 
49 years4.
The South African National Department of  Health 
(NDoH) implemented the first ART guidelines in 2004 
through the Strategic Plan for HIV and AIDS and the 
operational plan for Comprehensive HIV and AIDS 
Management, Care and Treatment for South Africa5 as 
part of  its public healthcare system and ART roll-out 
programme. This resulted in South Africa managing the 
largest ART programme in the world with 3.4 million 
people remaining on ART by the end of  20166,7,8.
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In 2013, the WHO emphasised that national policies 
should be developed for patients receiving third-line 
ART (TLART), as increased antiretroviral exposure and 
longer duration on ART would inevitably lead to more 
and more patients failing their first- and second-line 
ART due to drug resistance, increasing the need for 
more effective regimens for treatment-experienced pa-
tients9,10,11.
The South African NDoH implemented TLART guide-
lines for patients in 2015 who did not achieve viral 
suppression on their respective PI-based second-line 
regimens for a minimum of  12 months after receiv-
ing intensified adherence counselling, to be eligible for 
genotypic antiretroviral resistance testing (GART). If  
resistance to a boosted PI was confirmed, the Adult 
Group of  the Peer Review Committee for TLART 
from the NDoH would then consider the appropriate 
TLART for each individual patient12.
These TLART regimens are approximately five times 
more expensive than first-line ART13,14 and the contin-
ued increase in the number of  patients on TLART will 
further place a burden on the already constrained na-
tional healthcare budget14.  It is therefore paramount 
to effectively optimise patient management and care 
through rigorous policies and guidelines, especially in a 
resource-limited setting like South Africa.
The aim of  this investigation was to describe and report 
on the clinical characteristics and HIV resistance pat-
terns of  all adult patients who were initiated on TLART 
in three districts of  the North West Province in South 
Africa during the time of  this investigation.
Methods
Study design and population
This study was an all-inclusive retrospective descriptive 
investigation of  all adult patients approved for TLART. 
It was conducted in four main referral hospitals in 
three districts (Dr Kenneth Kaunda (DKK), Dr Ruth 
S. Mompati and Ngaka Modiri Molema) of  the North 
West Province in South Africa.
Inclusion criteria for this study were all adult patients 
(≥ 18 years) approved and already initiated on TLART 
by the end of  April 2017. These adult patients should 
have been on a PI-based second-line ART regimen 
for at least 12 months, with confirmed boosted PI 
resistance by means of  a GART performed by the Na-
tional Health Laboratory Service (NHLS) of  South Af-
rica, before TLART could be initiated.
Data collection and process
Health records from TLART approved adult patients 
were first accessed by the responsible pharmacist at 
the respective referral hospitals and then the data were 
anonymously and retrospectively captured onto a spe-
cifically designed case report form by the researchers.
The following demographical data were captured: date 
of  birth and gender.  Clinical markers (CD4 count and 
viral loads) for disease progression were captured at 
baseline (before any ART initiation, from 2002 onwards 
for this cohort) and at first- and second-line ART fail-
ure.
Time duration (in days) between HIV diagnosis and 
ARV initiation, duration on first-and second-line ART 
regimens and time spent between second-line failure 
and TLART initiation were recorded, including respec-
tive first- and second-line regimen combinations.
Genotypic antiretroviral test results, when patients 
experienced second-line ART failure, were captured 
for PIs, nucleoside reverse transcriptase inhibitors 
(NRTIs) and non-nucleoside reverse transcriptase 
inhibitor (NNRTIs) as susceptible, potential low-lev-
el, intermediate and high level resistance.  The NHLS 
incorporated the Stanford HIV Drug Resistance Da-
tabase (HIVDB) genotyping tool to determine HIV-1 
drug resistant mutations (http://hivdb.stanford.edu/).
Ethical clearance
Ethical approval was obtained from the Human Re-
search and Ethics Committee of  the North-West Uni-
versity (NWU-00340-16-A1), March 2017.  As this was 
a retrospective health record investigation with no direct 
contact with any of  the patients, no individual informed 
consent was obtained as this investigation would not 
have impacted on the treatment or care the patients 
would have received.  No personal data was captured.
Statistical analysis
Descriptive statistics were calculated by means of  IBM 
Statistical Package for the Social Sciences (SPSS®), ver-
sion 24. Median (interquartile range, IQR: 25th to 75th) 
was used for variables without a normal distribution 
and percentages (frequencies) were used for categorical 
variables.
Results
Twenty-four patients were approved and initiated on 
TLART by the end of  April 2017; only 21 adult pa-
tients met the set inclusion criteria, with three patients 
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younger than 18 years being excluded. Demographics 
and clinical characteristics of  the patients are present-
ed in Table 1. The median age at HIV diagnosis for 
this study population was 34 years (IQR: 30.2-36.8) and 
45 years (IQR: 39.5-47) at TLART initiation. Although 
HIV-1 subtype C is dominant in South Africa15, we 
were unable to record the specific HIV-1 subtype for 
this study population. The majority (95%, 20/21) of  
these patients were diagnosed as HIV positive from 
2004 onwards; one individual however was already di-
agnosed HIV positive in 2002.
The median baseline CD4 count was 69 cells/mm3 
(IQR: 40.8-127.8), at first-line ART and second-line 
ART failure the CD4 counts were, 79 cells/mm3 (IQR: 
26.5-124) and 119 cells/mm3 (IQR: 61.3-201.3).
The median baseline viral load (VL) was 98 000 copies/
ml (IQR: 45 569-820 000) and the VL at first-line and 
second-line ART failure were 100 000 copies/ml (IQR: 
42 085-248 852) and 73,196 copies/ml (IQR: 26 210 - 
197 007).
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Table 1:  Demographics and clinical characteristics of patients (n=21) initiated onto TLART 
Characteristics Median (IQR) 
Demographics   
Age (years) at HIV diagnoses 34 (30.3‒36.8) 
Age (years) at TLART initiation 
Female age (years) at TLART initiation (n=17) 




Clinical   
CD4 count at baseline (cells/mm3) 69 (40.8‒127.8) 
CD4 count at first-line failure (cells/ mm3)a 79 (26.5‒124) 
CD4 count at second-line failure (cells/ mm3) 119 (61.3‒201.3) 
VL at baseline (copies/ml) 98 000 (45 569‒820 000) 
VL at first-line failure (copies/ml)a 100 000 (42 085‒248 852) 
VL at second-line failure (copies/ml) 73 196 (26 210‒197 007) 
Durations (days)   
Durations between HIV diagnoses and ART initiationb 101 (36.5‒366.8) 
Duration on first-line ARTc 1 269 (765‒2 343) 
Duration on second-line ARTd 1 512 (706‒2 096) 
Duration between second-line failure and TLART initiationd 71 (57.5‒126) 
ART regimens   











(n=3) ABC/TDF/LPV/r; ddI/TDF/LPV/r; 
3TC/EFV/LPV/r 
ARVs used in TLART   
NRTI:                FTC (n=15), 3TC (n=6), TDF (n=10), AZT (n=4) d4T (n=1) 
NNRTI:             ETR (n=4)   
PI:                     DRV/r (n=21)   
INSTI:                 RAL (n=9), DTG (n=6)   
Median (IQR: 25th ‒ 75th ) 
a n=18, three patients not initiated onto recommended first-line ART regimens 
b n=18, three patients had missing data 
c n=17, three patients not initiated onto recommended first-line ART and one patients had missing data 
d n=20, one patient had missing data 
 
IQR, interquartile range; HIV, human immunodeficiency virus; TLART, third-line antiretroviral therapy; VL, viral load; ART, antiretroviral therapy; ARVs, antiretrovirals; 3TC, lamivudine; d4T, stavudine; EFV, efavirenz; 
TDF, tenofovir disoproxil fumarate; AZT, zidovudine; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; ddI, didanosine; ABC, abacavir; ETR, etravirine; DRV/r darunavir/ritonavir; DTG, dolutegravir; RAL, raltegravir; NRTI, 
nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor 
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Patients spent a median time of  101 days (IQR: 36.5-
366.8) between HIV diagnosis and ART initiation; 1 
269 days (IQR: 765-2 343) on first-line ART; 1 512 days 
(IQR: 706-2 096) on second-line ART and after failing 
their second-line ART regimen, patients waited a medi-
an additional 71 days (IQR: 57.5-126) for the approval 
and initiation of  TLART.
Complete data on first-line ART regimens (Table 1) 
were only available for 17 patients. The combination 
regimen of  lamivudine (3TC), stavudine (d4T) and efa-
virenz (EFV) was most often initiated (n=11) followed 
by 3TC, tenofovir disoproxil fumarate (TDF) and EFV 
(n=4).  One patient had missing data and three patients 
were initiated on ritonavir-boosted lopinavir (LPV/r) 
which is primarily reserved for second-line ART ac-
cording to the adult guidelines in South Africa5,12,16.
Complete data on PI-based ART regimens (Table 1) 
were available for 20 patients. The combination regi-
men of  3TC, zidovudine (AZT) and LPV/r was record-
ed most often (n=7) followed by 3TC, TDF and LPV/r 
(n=5).
The different combinations for TLART consisted of  
the following pharmacological classes and individual 
antiretroviral agents: NRTIs; emtricitabine (FTC), 3TC, 
TDF, AZT and d4T: NNRTI; etravirine (ETR): PI; 
darunavir/r (DRV/r): integrase strand transfer inhibi-
tors (INSTIs); dolutegravir (DTG); raltegravir (RAL).
Figure 1 reflects the most prevalent (> 15 %) vi-
ral     mutations to PI’s (major and minor), NRTIs and 
NNRTIs. Major mutations found against PI’s with the 
highest prevalence (n= 20) were M46I (n=15; 75%), 
V82A (n=13; 65%) and I54V (n=13; 65%). The fol-
lowing major mutations were less prevalent (5% respec-
tively) and not reflected here: V82V, V82S, V82C, V32I, 
M46M, M46L, L90M, L76L, I50V, I50L, I47A.
 
n = number of patients who presented with viral resistant mutations to NRTIs, NNRTIs, major and minor 
PIs as respective classes. It does not account for individual mutations as patients had more than one 
mutation 
The highest prevalence of  minor viral mutations to 
PIs (n=18) were for L10F (n=9; 50%), T74S and L33F 
(n=5; 27.7%). Less prominent minor mutations (5.6% 
respectively) not reflected here were for L89V, L89M, 
L89I, L10V, L10L, K43T, K20I, F53L, F53F, A71I, and 
A71A.
Viral resistance mutations to the NRTI drug class with 
the highest prevalence (n=19) were M184V (n=17; 
89.5%), D67N (n=6; 31.6%), M41L (n=5; 26.3%) and 
T215Y and V118I (n=4; 21.1%). The following muta-
tions were less prevalent: V75I, T215F, Q151M, L74V, 
L74L, L74I, K70R, K70N, K65R, F77L, F116Y, D67D, 
A62V (10.5% respectively) and Y115F, V75M, T69T, 
T69S, T69D, M184M, K70E, K219Q, K219E, F77F, 
D67G (5.3% respectively) not reflected in Figure 1.
Viral mutations identified within the NNRTI drug class 
with the highest prevalence (n=17) were K103N (n=8; 
47%) and G190A (n=4; 23.5%). Mutations with low-
er prevalence not reflected in Figure 1 were: Y188L, 
V108I, P225H, K238N, K103R, K103K, K101S, 
H221Y (11.8% respectively) and Y181C, V318F, V179V, 
V179I, V179D, V108V, V106M, V106I, N348N, N348I, 
K238S, K103S, K101R, K101P, K101H, K101E, 
H221H, F227L, E138G, E138E (5.9% respectively).
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Figure 1: Percentage of  most prevalent viral mutations to NRTIs, NNRTIs and PIs 
n = number of patients who presented with viral resistant mutations to NRTIs, NNRTIs, major and minor 
PIs as respective classes. It does not account for individual mutations as patients had more than one 
mutation 
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The total median number of  PI resistance (major and 
minor) found per patient was three mutations (IQR: 
2-3). The median number of  major (n=20) PI resistant 
mutations presented per patient was three (IQR: 3-4) 
and the median number of  minor (n=18) PI resistant 
mutations presented per patient was two (IQR: 2-3). 
The median number of  NRTI resistant mutations pre-
sented per patient was found to be three (IQR: 2-7) and 
the number of  NNRTI resistant mutations presented 
per patient was three (IQR: 2-4).
The individual drug resistance was reported as low, in-
termediate, high and susceptible. Results on the level of  
resistance to the following respective pharmacological 
classes, are presented in Tables 2 (PIs), 3 (NRTIs) and 4 
(NNRTIs) respectively.




Low Intermediate High Susceptible 
Atazanavir/r 14.3 28.6 57.1 0 
Darunavir/r 19.1 33.3 0 47.6 
Fosamprenavir/r 19.1 14.3 66.7 0 
Indinavir/r 4.8 14.3 80.9 0 
Lopinavir/r 14.3 9.5 76.2 0 
Nelfinavir/r 0 14.3 85.7 0 
Saquinavir/r 19.1 57.1 19.1 4.8 
Tipranavir/r 33.3 38.1 4.8 23.8 
  
        High-level resistance occurred for the following PIs: 
nelfinavir/r(NFV/r) (n=18; 85.7%), indinavir/r 
(IDV/r) (n=17; 80.9%), LPV/r (n=16; 76.2%), 
fosamprenavir/r (FPV/r) (n=14; 66.7%) and   
atazanavir/r (ATV/r) (n=12; 57.1%). None of  the 
TLART patients indicated high-level resistance to 
darunvir/r (DRV/r) with 47.6% reflecting susceptibility 
and all 21 patients received DRV/r as part of  TLART.




Low Intermediate High Susceptible 
Lamivudine 4.8 0 95.2 0 
Abacavir 47.6 9.5 42.9 0 
Zidovudine 4.8 0 42.9 52.4 
Stavudine 9.5 0 42.9 47.6 
Didanosine 47.6 9.5 42.9 0 
Emtricitabine 4.8 0 95.2 0 
Tenofovir 9.5 14.6 28.6 47.6 
  
High-level resistance occurred for the following 
NRTIs: 3TC and FTC (n=20; 95.2% respectively), 
ABC, AZT, d4T and ddI (n=9; 42.9% respectively) and 
TDF (n=6; 28.6%).
High-level resistance occurred for the following tested 
NNRTIs: nevirapine (NVP) (n=16; 76.2%) and EFV 
(n=15; 71.4%) with susceptibility of  23.8% for etravir-
ine and rilpivirine.  Access to etravirine is limited in the 
public sector and rilpivirine is only available in private 
sector in South Africa.
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Low Intermediate High Susceptible 
Efavirenz 4.8 14.3 71.4 9.5 
Etravirine 57.1 14.3 4.8 23.8 
Nevirapine 4.8 9.5 76.2 9.5 
Rilpivirine 38.1 19.1 19.1 23.8 
 
Discussion
The number of  patients on TLART will increase as 
more and more patients develop resistance to sec-
ond-line ART therapy10,11,17,18.  The financial burden of  
TLART13, which can be up to five times more expen-
sive, on a resource-limited country is enormous and any 
intervention that can prevent this will be valuable.
This was the first study, to our knowledge, that described 
the characteristics and identified possible trends in the 
clinical profile of  TLART patients in these three dis-
tricts of  the North West Province, taking into account 
certain clinical, demographical variables and resistance 
data. The majority (81%) of  this small study popula-
tion were female which is not surprising as sub-Saharan 
woman have on average a 60% higher risk of  being in-
fected with HIV19.
Patients in our study population had a median age of  
34 years at HIV diagnosis, similar to other much larger 
studies conducted in Soweto, South Africa during 2011, 
in United States of  America (USA) during 2000-2009 
and the INSIGHT START study20,21,22. The reproduc-
tive age range (15-49 years) receives more focus in re-
search studies as this group is more prone to be sexually 
active and thus at greater risk of  acquiring HIV infec-
tion4,23, despite assumptions that HIV is less relevant 
in older generation (> 49 years) they should also be in-
cluded in more studies23.
The median age of  TLART initiated patients in our 
study population was 45 years, indicating a median time 
difference between HIV diagnoses and TLART initi-
ation of  at least 8.1 years.  Published data on demo-
graphics of  patients on TLART are limited, but a South 
African study reported a median age of  44 years when 
initiated onto salvage therapy and the median duration 
on ART prior to salvage was 8.9 years in a study con-
ducted in the private sector24. These patients (n=152) 
were enrolled in the Aid for AIDS (AfA) programme 
with salvage therapy being readily available from July 
2007, contrary to the public sector rolling out TLART 
only from March 201325.
This study’s low median CD4 count of  69 cells/µL 
(41-128) at baseline was similarly reported in studies in 
KwaZulu Natal (2011 to 2014) of  94 cells/µL (2-384) 
and another large multicentre study (2000 to 2008) in 
South Africa which reported 96 cells/µL (40-159)26,27. 
It is important to note that majority of  baseline data for 
this descriptive investigation was recorded from 2004, 
when it was standard care for HIV positive patients to 
be first initiated onto co-trimoxazole prophylaxis treat-
ment until they were eligible for ART with a CD4 count 
of  <200 cells/µL (2004-2010 guidelines) and <350 
cells/µL (2013 guidelines) as recommended by the na-
tional ART guidelines of  that time5,16,25. The low CD4 
count at baseline and median 101 days (37-363) before 
first-line ART was initiated in this study population is 
evident from following these earlier guidelines.
Two randomised controlled trials (START and TEM-
PRANO ANRS 12136) addressed the optimal time to 
initiate ART and both studies indicated a significant 
clinical benefit from initiating ART in patients with a 
CD4 count > 500 cells/µL, rather than waiting for a 
patient`s CD4 count to reach a minimum threshold22,28. 
Further studies illustrated that in order to improve the 
lost to follow-up due to missed appointments by pa-
tients to initiate ART, patients can safely and effectively 
be initiated onto ART on the same day of  HIV diagno-
sis29,30 or within 14 days of  ART eligibility31. The strat-
egy to initiate ART irrespective of  CD4 count or to 
“test and treat” has since been implemented in South 
Africa12,32 and recommended by the WHO33. 
A large South African study conducted in nine HIV 
clinics between 2004 and 2013 identified age, gender, 
a constant low CD4 count during ART and appoint-
ments missed during the first six months (non-adher-
ence) as the strongest predictors of  first-line ART fail-
ure34. In this study population, the median CD4 count 
remained very low at both first-line ART failure and at 
second-line ART failure (79 and 119 cells/µL respec-
tively) indicative of  a consistently low CD4 count for 
the total median duration on ART.  The lowest CD4 
count reported in this study population (HIV diagno-
sis to TLART-initiation) was 3 cells/µL, although non 
adherence could not be reliably evaluated, it may be 
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possible that sustained low CD4 count could also have 
contributed to ART failure.
Taking into account the consistently low CD4 results, it 
is important to note the much higher median baseline 
VL of  98 000 copies/ml (45 569–820 000) compared 
to the large cross sectional study in Soweto, South Af-
rica, (n=4 793) during 2011 with 13 000 copies/ml (2 
050–98 171) and higher CD4 count compared to this 
study population20.
In one of  the largest studies (n=19 645) from five pub-
lic-sector facilities in South Africa where adults com-
pleted a minimum of  6 months on ART, the reported 
first-line failure at five years on treatment was 8-17% 
depended on the definition of  confirmed virological 
failure27.  In this study the median VL at first-line fail-
ure was 100 000 copies/ml (42 085-248 852).  At sec-
ond-line failure the median VL was 73 196 copies/ml 
(26 210-97 007) for this study population which was 
similar to the private sector study (n=152 patients) with 
82 831 copies/ml (20 060-233 778) that were initiat-
ed on salvage therapy during 2007- 2011 at second-line 
ART failure24.  Possible reasons for the high viral loads 
observed in this study at first-and second-line failure 
could be due to adherence issues (not monitored in this 
retrospective study) but also possibly long periods on 
failing regimens before ART was switched.
Major PI mutations are generally defined as “mutations 
that by themselves reduce the susceptibility to one or 
more drugs”. Minor mutations are defined as having 
“little or no effect on susceptibility” and are sometimes 
also referred to as accessory, as they “reduce suscep-
tibility only in combination with a major mutation or 
increase the replication fitness of  viruses containing 
major drug resistance mutations”35,36.
Although up to 40% of  adults in South Africa on 
PI-based second-line regimens experience virologi-
cal     failure37, all contributing risk factors have not 
been clearly accounted for. Due to the inclusion criteria 
of  this study, a patient had to have documented resist-
ance to a boosted PI after being treated with a PI-based 
second-line ART regimen for a minimum of  12 months 
before they could be considered for GART eligibility 
and TLART. It was therefore to be expected that 100% 
of  this study population experienced high-level resist-
ance to ≥1 PI, and 95.23% had ≥ 1 major PI mutation 
at the time GART was performed. The total median 
number of  protease mutations (major and minor) found 
per patient in this study was 3 (IQR: 2-3) at the time of  
GART after spending a median 4.1 years on second-line 
treatment.  Meintjes and co-workers reported that 75% 
of  their AfA private setting (n=152) cohort who 
qualified for salvage therapy with a median duration of  
5.1 years on PI-based regimens presented with ≥ 3 ma-
jor protease mutations24. Protease inhibitor resistance 
mutations in a large public health study by van Zyl and 
co-workers (2013) reported that 11% of  the patients 
on LPV/r had > 1 LPV resistant mutations but they 
did not report on the median duration of  the LPV/r 
treatment38.
It is important to consider that PI resistance requires 
consecutive accumulation of  mutations with on-go-
ing exposure to a non-suppressive PI-based ART 
regimen39. The accumulation of  protease mutations was 
closely linked to the time spent on a failing second-line 
ART regimens in studies conducted in Vietnam and 
Cambodia where different HIV-1 subtypes were rele-
vant compared to South Africa40,41.
Adult patients failing second-line treatment for a 
duration of  0-12 months and > 24 months had me-
dian of  2 (0-5) and 5 (0-6) protease mutations (major 
and minor) per patient respectively, in a Nigerian co-
hort (n=61). They further estimated that 0.6 protease 
mutations  developed for every six months they were 
maintained on a failing second-line regimen but re-
ported that 38% of  patients failing second-line ART 
did not have any protease mutations9. Chimbetete and 
co-workers reported that 51% of  their participants 
(n=86) had major protease mutations, 14% and 12 % 
had 3 or 2 PI mutations respectively at second-line ART 
failure with a median duration of  2.6 years on a PI-
based regimen in Zimbabwe42. Contradictory to our 
study and the above mentioned studies no major re-
sistance to PIs was reported in a study conducted in 
Gugulethu, a HIV referral centre in the Western Cape, 
with reported second-line ART failure in adult patients 
(n=43). These patients were on second-line treatment 
for a mean duration of  10 months and plasma samples 
were only taken after a mean period of  7 months post 
confirmed failure was first reported.  They did however 
report that 91% of  the individuals had minor protease 
mutations37. Another study at two clinics in Johannes-
burg (n=75) reported that 39% of  patients failing sec-
ond-line regimen (LPV/r and 2 NRTIs) did not have 
resistance mutations to protease or reverse transcriptase 
after spending an average of  16 months on second-line, 
suggesting that non-adherence could have contributed 
to the treatment failure18.
Other important risk factors that may lead to virological 
failure such as adherence should not be underestimated 
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in the development of  mutations and thus treatment 
failure. The Zimbabwean cohort study was conducted 
in patients with considered good adherence, they could 
therefore conclude that the regimen failure was due 
to resistance and not lack of  adherence. They further 
established a significant association between age (>24 
years, p=0.003) and the development of  major PI re-
sistance and concluded that resistance was less prone 
in adolescents and young adults due to lack of  adher-
ence42.
In this study, the total median duration on first- and 
second-line ART was median 42.3 and 50.4 months re-
spectively. According to South Africa’s national ART 
guidelines of  2015, a patient experiencing virological 
failure on a PI-based second-line ART regimen should 
be checked for tolerability and drug-drug interactions, 
and receive intensified adherence counselling before 
the VL can be repeated after 180 days12. Taking into 
account the additional time prior to actual TLART 
initiation (median 71 days) and adding the guideline’s 
recommended waiting time prior to VL repeat (180 
days) could have resulted in approximately 251 days 
(≈ 9 months) spent on a failing second-line ART regi-
men before TLART was initiated. The importance of  
shortening the period between identifying second-line 
ART failure and initiating TLART is vital to minimise 
the number of  protease mutations formed during 
prolonged time spent on failed second-line ART, was 
highlighted by various groups9,40,41,42. In this study all pa-
tients were older than 24 years and resistant to various 
PI’s, neither adherence nor the HIV-1 subtype could be 
accounted, the median duration exposed to second-line 
was 50.4 months with approximately 9 months spent 
on failed second-line ART.
The three major PI mutations found in this study 
population with the highest prevalence were M46I 
(75%), I54V and V82A (65%).  The major PI mutations 
present in the AfA private setting cohort who qualified 
for salvage therapy were in agreement with most of  the 
major PI mutations found in this study population32. 
The major protease mutations most prevalent in 61 Ni-
gerian patients failing their respective second-line ART 
between 2004 and 2011 were I54V, V82A, L10I and 
M46I9. Although results from the Gugulethu Clinic re-
ported no major PI mutations they did however detect 
minor resistance mutations in 91% of  their patients37.
M46I is a nonpolymorphic mutation which is primarily 
selected by IDV, NFV, FPV, ATV and LPV and usually 
has a prevalence of  20% in treatment-experienced pa-
tients. M46I furthermore presents alone or in combina-
tion with mutations V32I, I47V, L76V, I84V and L90M 
as was the case in this study as well. The prevalence of  
V82A and I54V mutations do not present in combi-
nation with M46I, they usually occur in combination 
with M46V, not present in this study population. Mu-
tation V82A is a nonpolymorphic substrate-cleft muta-
tion. It reduces the susceptibility to IDV and LPV and 
linked with cross-resistance to ATV and NFV.   Lastly, 
mutation I54V is also a nonpolymorphic mutation, 
largely  selected by IDV and LPV and decreases the 
susceptibility of  all the PI`s, except for DRV/r36. This 
is also possibly why 100% of  the patients in this cohort 
were initiated on DRV as part of  their TLART, as this 
cohort had a 0% high level resistance, 19% low-level 
resistance, 33% intermediate resistance and 48% sus-
ceptibility to DRV.
The emergence of  PI cross-resistance mutations also 
played a role in this study, with the highest level of  re-
sistance against NFV (86%), IDV (81%), FPV (67%) 
and ATV (57%) even though these patients were only 
treatment-experienced on LPV/r. This observation of  
cross resistance development to other PI’s has been well 
documented previously38,41. PI`s share similar chemical 
structures, therefore cross-resistance is often observed 
and clarifies the observation of  patients experiencing 
high-level resistance to PI`s they were never previously 
been exposed to43.
Considering the latter, we acknowledge that all the 
mutations reflected in figure 1 synergistically and ho-
listically affected the level of  resistance found in this 
study population, but the clinical effects of  the muta-
tions, as described in the Stanford University HIV Drug 
Resistance Database, can be seen in the data of  this 
study population and is a valuable contribution to the 
resistance mutation data on TLART patients in South 
Africa.
Resistance mutations for the NRTI`s with the highest 
prevalence were M184V (89.5%) followed by the thymi-
dine analogue mutations (TAM’s), D67N (31.6%) and 
M41L (26.3%). These frequencies corresponded with 
recent results from the Zimbabwean cohort who  re-
ported 67% prevalence for M184V and 36% for D67N42 
and a Nigerian cohort with 66% for M184V, 43% for 
M41L and 34% for D67N9 in patients who failed sec-
ond-line ART during 2004-2011. M184V is the most 
prominent NRTI mutation in Africa and mainly affects 
resistance to 3TC and FTC as was also shown in this 
study and others42,43,44.
The M184V mutation is clinically significant as it is 
primarily selected by 3TC and FTC and reduces the 
susceptibility of  both these drugs by >100 fold, but in 
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contrast causes an increase in the susceptibility to AZT, 
d4T and TDF and decreases the rate at which AZT, 
d4T and TDF resistance occurs36. This high prevalence 
(89.5%) of  the M184V mutation found in this study 
population can possibly be attributed to the number of  
patients who were initiated on a 3TC based first-line 
(76%) and second-line ART regimen (71%). It is evi-
dent that this M184V mutation had a significant effect 
on 3TC and FTC resulting in 95% high-level resistance, 
but M184V may have contributed to the increased sus-
ceptibility to AZT (52%), d4T and TDF (48%) although 
other factors may have had an impact. The TAM’s, in 
this case D67N and M41L, are known to accumulate 
in patients who remain on a failing ART regimen45,46. 
Unfortunately GART results were not available at first-
line failure for this study cohort.  If  these mutations 
were thus already present when switched to second-line 
ART they could have negatively impacted the sec-
ond-line treatment45,46 notwithstanding the long dura-
tion on failed second-line therapy in this small cohort.
High-level resistance to NNRTI`s were found for NVP 
(76.2%) and EFV (71.4%) and mutations most prev-
alent for NNRTI`s were K103N (47%) and G190A 
(23.5%). Mutation K103N is a nonpolymorphic mu-
tation that primarily selects for NVP and EFV and 
reduces the susceptibility of  these drugs by fifty- and 
twentyfold respectively. Mutation G190A is also a non-
polymorphic mutation that primarily selects for NVP 
and EFV36. Major NNRTI mutations found in the Ni-
gerian cohort9, for patients failing second-line ART 
between 2004-2011, were K103N, Y181C (26%) and 
G190A (16%). The Y181C mutation was much less 
prevalent in this study at 5.9%.
It was not clear why three patients were initiated 
on regimens containing LPV/r, primarily reserved 
for second-line ART in adults in South Africa since 
20046,13,14,15,16,24. Reasons such as drug intolerability, 
drug-drug interactions, missing health information or 
not accurately recorded dates and possible errors in fol-
lowing the national ART guidelines may have played a 
role.
This study had several limitations that need to be 
taken into consideration. Adherence to ART could not 
be accurately investigated retrospectively and although 
this was an all-inclusive sample, only a small number of  
patients were initiated on TLART in the North West 
Province during this investigational period. Baseline 
GART testing did not form part of  the South African 
guidelines and thus prior resistance data was not avail-
able until patients were considered for TLART. Due 
to the retrospective nature of  this study, incomplete 
patient health records could have contributed to vital 
missing information.
Conclusion
The increase in the number of  TLART patients in fu-
ture will place a significant financial and infrastructural 
burden on South Africa. This small descriptive study 
contributed and improved the knowledge on the clin-
ical characteristics and resistance patterns of  TLART 
patients in order to improve and optimise HIV manage-
ment and care of  these patients living in a resource lim-
ited setting, such as the North West Province, in South 
Africa.
The major NRTI mutations identified were M184V, 
D67N and M41L, major NNRTI mutations were 
K103N and G190A and the major PI mutations were 
M46I, V82A and I54V. The large extent of  PI cross-re-
sistance found amongst these patients predominantly 
on LPV/r was described previously but it highlights the 
importance of  more frequent and earlier GART testing, 
although costly, as patients spent longer durations on 
failing ART regimens.  This will enable the   prescriber 
to choose maximum suppressive ART combinations to 
be used as soon as possible.  
This is the first study, to our knowledge, reporting on 
the different time duration post diagnosis, on various 
ART regimens and resistance patterns of  adults on 
TLART in these districts. It highlights the median 71 
days between documented second-line ART failure and 
the actual initiation of  TLART and the enormous bur-
den this system is already facing in the relatively early 
phases of  TLART initiation.
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